SNCA and Parkinson disease: An enzyme-linked immunosorbent assay (ELISA) has been developed to assess the levels of α-synuclein, as a candidate biomarker, and several recent papers have demonstrated changes of α-synuclein levels in the cerebrospinal fluid (CSF) of patients with PD.